Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme

NCT00768911 is registered in ClinicalTrials.gov with Adnexus, A Bristol-Myers Squibb R&D Company as lead sponsor.

NCT NCT00768911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00768911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme
Lead sponsor
Adnexus, A Bristol-Myers Squibb R&D Company
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2008
Completion date
June 30, 2011
Enrollment
30 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme